Following its integration into Bora Group, SunWay Biotech Co., Ltd. has demonstrated significant operational synergies, reporting consolidated revenue of NT$970 million for 2024—a 69.9% year-over-year increase. The company achieved a gross profit margin of 56%, while net income surged 155.3%, reaching NT$110 million. With earnings per share (EPS) of NT$1.96, the company has proposed a cash dividend of NT$1.33 per share.

Strategic Expansion and Business Synergy Yield Strong Growth

Compared to 2022 standalone financials, SunWay’s expanded scale and strengthened distribution channels under Bora Group have led to a 176.8% increase in consolidated revenue and a 113.3% rise in gross profit. As the company advances into deeper integration phases, it is poised to unlock operating leverage effects in 2025, further driving profitability.

Bora Group Chairman, Bobby Sheng, emphasized that since SunWay’s acquisition in 2023, the company has rapidly implemented a three-pronged strategy, focusing on:

1. Health supplement ingredient innovation,
2. Prescription pharmaceuticals, and
3. Branded nutraceuticals.

By integrating proprietary ingredient development, product strategy, and global distribution networks, Bora has maximized cross-sector synergies, leveraging its expertise in both the pharmaceutical and global health supplement markets.

Innovative Health Supplements Gain Global Attention

SunWay has continued to strengthen its proprietary ingredient technology, with a strategic focus on microbial fermentation for supplement development. Recently, it launched two breakthrough products—Monafit and ExoBDNF—which have already garnered attention from international markets including Europe, the U.S., and China.

• Monafit: Formulated with a novel Monascus (red yeast) strain, this supplement supports metabolism and physiological balance for overall health maintenance.
• ExoBDNF: A probiotic supplement containing extracellular vesicles, designed to modulate gut microbiota and support digestive function. This product is rooted in the gut-brain axis concept, offering nutritional support for neurological health.

Global Market Expansion: Southeast Asia in Focus

In late 2024, SunWay partnered with Great Tree Pharmacy to establish GTSW Bio in Malaysia, marking a strategic entry into Southeast Asia. The company’s first proprietary product, Vascuxin, formulated with Ankascin 568, successfully launched across 600 Big Caring Group pharmacy locations, paving the way for further regional expansion.

Pharmaceutical Portfolio Strengthens Market Presence

Beyond supplements, SunWay is actively expanding its prescription drug business. Key neurology-focused pharmaceuticals, including:

• Ridonine (Parkinson’s disease treatment)
• Longbo Mint (antidepressant film-coated tablets)

These products have gained traction in leading hospital networks, driving double-digit pharmaceutical revenue growth in 2024. By 2025, SunWay aims to leverage its expertise in CNS (central nervous system) therapeutics to introduce its branded nutraceuticals into the neurology healthcare sector, further solidifying its market position.

With a robust product pipeline, international expansion strategy, and continued innovation, SunWay Biotech Co., Ltd. is well-positioned for sustained growth in both the pharmaceutical and health supplement industries.

Resource: 晨暉併入保瑞集團綜效 去年三率三升、擬配息1.33元